Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Progression-free Survival

Median time until disease progression. Disease progression defined as radiological and/or symptomatic disease progression or death in absence of progression.

Time frame: Until time of disease progression, as assessed every 21 days (maximum 28.8 months)

Overall Survival at 12 Months

Percentage of patients alive after 12 months of study treatment

Time frame: 12 months from 1st dose

Overall Survival

Median number of months from first study treatment until time of death

Time frame: From first study treatment until time of death (maximum 29.0 months)

Best Tumor Response

Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor larger than at baseline

Time frame: While receiving study treatment; assessed every 21 days until progression (maximum 28.8 months)

Duration of Tumor Response

Median length of time that tumor showed any type of response, ie, CR, PR, or SD

Time frame: While receiving study treatment; assessed every 21 days until progression (maximum 28.8 months).